









© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine 
Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 
jc.2020-01870 See https://academic.oup.com/endocrinesociety/pages/Author_Guidelines for 
Accepted Manuscript disclaimer and additional information. 
A PILOT STUDY OF GUT-BRAIN SIGNALING AFTER OCTREOTIDE THERAPY 
FOR UNINTENTIONAL WEIGHT LOSS AFTER ESOPHAGECTOMY 
Conor F. Murphy, MD
1,2
; Nicholas Stratford, MSc
1
; Neil G. Docherty, PhD
1
; Brendan Moran, MD, 
MCh
1
; Jessie A. Elliott, MD, PhD, MRCS
1,2
; Marie-Louise Healy, MD, MRCPI
3
; Jason P McMorrow, 
MD, PhD
4
; Narayanasamy Ravi, MD, FRCS
2
; Anthony P Goldstone, MD, PhD, MRCP
5
, John V. 
Reynolds, MD, FRCS
2





1. Diabetes Complications Research Centre, Conway Institute of Biomolecular and Biomedical 
Research, University College Dublin, Dublin 4, Ireland. 
2. National Oesophageal and Gastric Centre, Trinity Centre for Health Sciences, Trinity College 
Dublin and St. James’s Hospital, Dublin 8, Ireland. 
3. Department of Endocrinology, St. James’s Hospital, Dublin 8, Ireland. 
4. Department of Radiology, St. James’s Hospital, Dublin 8, Ireland. 
5. PsychoNeuroEndocrinology Research Group, Centre for Neuropsychopharmacology, Division of 
Psychiatry, and Computational, Cognitive, and Clinical Neuroimaging Laboratory, Department of 
Brain Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London W12 





















Correspondence: Professor Carel le Roux, Metabolic Medicine Group, Conway Institute of 
Biomolecular and Biomedical Research, University College Dublin, Dublin 4.  
Email: carel.leroux@ucd.ie 
Funding: Supported by a scholarship award from the Irish Cancer Society, Ireland, to CFM 
(CRS17MUR). 























Recurrence-free patients after esophageal cancer surgery face long-term nutritional consequences, 
occurring in the context of an exaggerated post-prandial gut hormone response. Acute gut hormone 
suppression influences brain reward signaling and eating behavior. This study aimed to suppress gut 
hormone secretion and characterize reward responses and eating behavior among post-esophagectomy 
patients with unintentional weight loss. 
 
Methods 
This pilot study prospectively studied post-operative patients with ≥10% body weight loss (BWL) 
beyond one year who were candidates for clinical treatment with long-acting Octreotide (LAR). 
Before and after four weeks of treatment, gut hormone secretion, food cue reactivity (functional 
MRI), eating motivation (progressive ratio task), ad libitum food intake, body composition, and 
symptom burden were assessed. 
 
Results 
8 patients (7 male, age: mean±SD 62.8±9.4 years, post-operative BWL: 15.5±5.8%) participated. 
Octreotide LAR did not significantly suppress total post-prandial plasma GLP-1 response at four 
weeks (P=0.08). Post-prandial symptom burden improved after treatment (Sigstad score 
median(range): 12(2-28) vs. 8(3-18), P=0.04), but weight remained stable (Pre:68.6±12.8kg vs. 
Post:69.2±13.4kg, P=0.13). There was no significant change in brain reward system responses, during 
evaluation of high-energy or low-energy food pictures, nor their appeal rating. Moreover, treatment 























The protocol used made it feasible to characterize the gut-brain axis and eating behavior in this 
cohort. Inadequate suppression of gut hormone responses four weeks after Octreotide LAR 
administration may explain the lack of gut-brain pathway alterations. A higher dose or shorter inter-
dose interval may be required to optimize the intervention. 
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Unintentional weight loss and gastrointestinal symptoms associated with malnutrition and impaired 
functional recovery are serious and common concerns for patients after esophagectomy, even among 
those who remain free from recurrent disease in the long-term (1-4). In addition to weight loss, 
malnourished patients may have sarcopenia and osteopenia (5-7). These issues accentuate the 
psychosocial burden experienced by patients post esophagectomy, impairing physical function and 
long-term health-related quality of life (HRQL) (8-10). Though there are myriad drivers of weight 
loss following esophageal cancer surgery, the impact of exaggerated post-prandial gut hormone 
signaling on appetite and satiety has emerged as a novel modifiable factor (11). This has more 
thoroughly been researched in bariatric surgery contexts and is relatively understudied post-
esophagectomy (12-14). However, targeted therapies, specifically modulating the gut-brain axis by 
suppressing gut hormone secretion, such as somatostatin analogues, have considerable theoretical 
rationale. 
 
Scientific understanding of neural and hormonal pathways linking the gut to the brain is evolving. The 
dopaminergic mesolimbic pathway is the cornerstone of hedonic signaling, which together with 
hypothalamic homeostatic pathways control food intake and eating behavior, and this is influenced by 
feeding status, energy balance, perceived momentary value of food, and past learned experiences (15-
19). Taking a reductionist approach, eating behavior can be viewed as the sum of appetitive and 
consummatory behaviors, with the former representing, in this case, a positive motivation to seek food 
(‘wanting’), and the latter, the actual consumption of food, which is intimately linked with, and driven 
by, anticipatory and actual food ‘pleasure’ or reward (‘liking’) (20, 21). Though methodologically 
challenging, it may be possible to measure appetitive behavior through techniques validated in 
bariatric research. Functional MRI and progressive ratio tasks (12), circumvent the limitations 
associated with self-reported methods, which are hypothesis-generating but prone to biases (22-24). 





















characterizing consummatory behavior (25, 26). Measuring both appetitive and consummatory 
components of eating behavior in parallel with gut hormone signaling may provide insight into 
changes in gut-brain signaling, and the impact of potential therapeutic strategies. 
 
In the context of esophageal cancer surgery, the mechanisms by which gut hormones, such as 
glucagon-like peptide-1 (GLP-1) may influence eating behavior, symptomatology, and nutrition after 
surgery are becoming increasingly understood. Acute suppression of the exaggerated satiety gut 
hormone response using the somatostatin analogue Octreotide can increase ad libitum food intake by 
50 per cent (27). Octreotide also increased motivation to eat in the acute setting, inducing a stronger 
desire to obtain a sweet-fat stimulus.(28) Several aspects of gut-brain signaling, however, remain 
unexplored in this operative context. First, the association between gut hormone suppression therapy 
post-esophagectomy and anticipatory food reward on fMRI is unknown. Second, how a short course 
of Octreotide therapy affects gut hormone signaling and eating behavior has not been reported. In 
various clinical contexts associated with weight loss and dumping syndrome, long-acting Octreotide 
(Octreotide LAR), which can reduce post-prandial symptoms and induce weight gain, has been used 
for decades (29, 30). However, there is a dearth of evidence regarding how best to employ this 
treatment paradigm to ameliorate excessive post-operative weight loss, currently limiting the viability 
of this targeted treatment approach. Parallel assessment of gut hormone signaling, food reward 
response, and eating behavior has not been performed previously but such a methodological approach 
may facilitate both a greater understanding of post-esophagectomy physiology and the therapeutic 
benefit of long-acting somatostatin analogue therapy. 
 
It is within this context that this pilot study sought to: a) comprehensively characterize the gut-brain 
signaling pathway in a post-esophagectomy cohort, b) assess gut hormone and brain reward system 
food cue reactivity associated with a 4-week course of Octreotide LAR therapy, and c) determine the 





















MATERIALS AND METHODS 
Participants 
We recruited patients who were disease-free at least 1 year post curative intent esophagectomy with 
gastric conduit reconstruction for esophageal cancer, who had ≥10% unintentional weight loss and 
were scheduled to receive Octreotide LAR as a trial of therapy to improve weight. All patients had a 
significantly raised Sigstad score (>7) or persistent lack of appetite. First treatment dose was given in 
the outpatient clinic, with a shared decision made with each patient based on whether to continue 
based on treatment response after four weeks. Response was assessed using self-perceived 
improvement based on questionnaire scores as well as objective changes in appetitive behaviour and 
weight. Exclusion criteria included: nutritional compromise due to overt issues such as anastomotic 
stricture with significant dysphagia or significant malabsorption of any cause, the presence of 
neuropsychiatric illness, the presence of alcohol or other substance misuse disorders, 
contraindications to the use of Octreotide LAR. 
 
Study Design and Protocol 
This study was approved by the regional research ethics committee (2017-07 (6)) and it was 
undertaken in accordance with the principles of ICH Good Clinical Practice with written, informed 
consent obtained from all participants. The study was prospectively registered on ClinicalTrials.gov 
(NCT03377660). Participants were studied on two occasions, before and four weeks after an 
intramuscular dose of 10mg Octreotide LAR (Figure 1), as used previously to treat dumping 
syndrome in the post-gastrectomy context [Penning, 2005 #7], which was accompanied by a 
prophylactic course of pancreatic enzyme replacement therapy. At each visit, participants attended the 
Clinical Research Facility at 08:45 having completed a 12-hour fast, excluding water and regular 
medications. The protocol had four components, all of which were completed on the same day. These 
included (a) standardized mixed meal challenge, (b) functional MRI tasks, (c) progressive ratio task, 






















Mixed meal challenge  
Venous blood samples were drawn before, and at 30, 60, 90, 120, and 150 minutes after a 400 kcal 
standard semi-solid mixed meal (160 g (184 mL): 61.0% fat, 6.7% protein, 32.3% carbohydrate). 
Using a 10 cm visual analogue scale recorded at each blood sampling time point, temporal patterns of 
hunger, nausea, desire to eat, prospective food consumption, fullness, and sleepiness were measured. 
A composite appetite score was also calculated based on VAS scores, based on the following formula: 
[hunger + (100 – fullness) + desire to eat + prospective food consumption] / 4 (31). 
 
Each participant completed European Organization for Research and Treatment of Cancer (EORTC) 
HRQL questionnaires (General HRQL: QLQ-C30, and cancer-specific sections: QLQ-OES18 and 
QLQ-OG25) (32, 33), as well as a Sigstad post-prandial dumping syndrome questionnaire and a 
modified gastrointestinal symptom rating scale (32). The Sigstad score is a questionnaire utilized in 
the diagnosis and assessment of post-operative dumping syndrome, with a score greater than seven 
indicative of clinically significant dumping syndrome. Body weight and body composition were 
assessed using bio-electrical impedance analysis (BIA, Seca 515, Seca GMBH & Co., Hamburg, 
Germany) with participants wearing light clothing, post voiding of urine, as per best practice (34, 35). 
 
Functional MRI Tasks 
Study participants then underwent both structural and functional magnetic resonance imaging  (fMRI) 
scanning over a 60 minute period, from 180 – 240 minutes, following a previously described protocol 
(12, 36-38). During this period they performed a food picture evaluation fMRI task in which they 
rated the appeal of pictures of high-energy foods, low-energy foods and objects (12, 36-38), followed 
by a control auditory-motor-visual (AMV) task (38). For the food picture evaluation fMRI task, the 
effects of Octreotide LAR treatment on blood oxygen level dependent signal (BOLD) was examined 





















amygdala, anterior orbitofrontal cortex (OFC), anterior insula) and whole brain analysis for the 
following picture contrasts: high-energy > low-energy food, high-energy food > object, low-energy 
food > object, nor any food (high-energy or low-energy food) > object. A detailed description of the 
fMRI methodology is included in the Supplementary methods(39). 
 
Progressive Ratio Task 
Participants were asked at each visit to complete a computer-based progressive ratio task (PRT) 
following the fMRI, as per a previously described protocol [Goldstone, 2016 #2957;Miras, 2012 
#3625]. This validated paradigm involves using a sweet-fat stimulus to gauge motivation or desire to 
eat. Each session lasted for up to 15 minutes (or upon cessation of the task by the participant 
themselves) and was performed once before and once after treatment with Octreotide LAR. 
Participants were asked to click the computer mouse in order obtain the candy reward reinforcer. The 
number of required clicks to receive the reward increased from 10, at the first stage, in a geometric 
increment of two (10, 20, 40, 80, 160, 320 clicks etc.), with the final completed increment referred to 
as the ‘PRT breakpoint’. At each stage, the computer program instructed participants to ingest a single 
reward. It then urged participants to continue clicking the mouse, if they so desired, to obtain the next 
reward. They could continue clicking or stop at any point when the arduousness of the task 
outweighed the perceived value of the food reward. Visual analogue scales were completed, and 
blood samples taken, immediately before the PRT and after the subsequent buffet meal. 
 
Ad libitum buffet meal 
The final test was a buffet meal paradigm, conducted in a research kitchen, which used a direct 
measures approach to assessing macronutrient intake and preference based upon a method created and 
validated by Geiselman et al (40). When recruited to the study, participants completed a screening 
food preference questionnaire, which was used to inform the 18 food items that comprised the 





















groupings, of which three were high-fat and three were low-fat. Within each trio, the carbohydrate 
(complex and simple) and protein content varied. Quantities of each of the 18 foods were provided in 
excess to ensure there was no limit to ad libitum consumption, which could introduce bias. 
Participants were not aware that macronutrient type and quantity ingestion was being measured, with 
foods weighted prior to testing. Instead, participants were informed that in order to optimize the post-
prandial stimulation of gut hormones, they should consume the foods they liked until they were 
comfortably satiated. This 45 minute study stage was followed by a final blood draw and VAS score 




Once drawn, blood samples were placed on ice and carried to the laboratory in an adjacent room. 
They were immediately centrifuged at 2500 rpm at 4C for 10 minutes, with plasma then stored at -80 
C to minimize sample degradation. Plasma total GLP-1 levels were measured by sandwich enzyme-
linked immunosorbent assay (ELISA) (GLP-1 Total ELISA, Merck Millipore, Darmstadt, Germany). 
The assay used was sensitive, validated to detect above 1.5 picomolar (pM) with a 50µL sample, and 
specific, having no cross-reactivity with GLP-2, GIP, glicentin, or oxyntomodulin. The intra- and 
inter-assay co-efficient of variation were <2%, and <12%, respectively. Plasma glucose and insulin 




This was a pilot study with the principal aim to determine feasibility of the protocol and effect size of 
the outcomes. When planning the study we used the PRT breakpoint as primary outcome as our 
previous data demonstrated that the difference in the response of matched pairs to Octreotide is 





















significance level of 0.05 and 0.9 power, then 5 participants would be needed to detect a difference 
with Octreotide LAR treatment.  
 
Statistical analysis 
GraphPad Prism (version 8.3) for macOS (GraphPad software (San Diego, CA, USA)), was used for 
data analysis. As per EORTC recommendations, a linear transformation of EORTC questionnaire 
responses into numeric values ranging from 0-100 was conducted, with rising scores indicating 
increased symptom severity or improved quality of life scores. Data were reported as mean ± standard 
deviation, or median (range), as appropriate, unless otherwise specified. Area under the curve (AUC) 
was calculated using the trapezoidal rule. Inferential testing for within-group univariate comparisons 
involved paired Student’s t or Wilcoxon signed rank tests, as appropriate. To test for significant 
differences within individual variables over multiple timepoints, one-way repeated measures analysis 
of variance (ANOVA) with post-hoc Bonferroni’s multiple comparisons test employed, unless 
otherwise stated. In the case of two or more variables followed over time, two-way repeated measures 
ANOVA with post-hoc Bonferroni multiple comparisons test used. Continuous variable inter-
relationships were determined using simple linear regression. Effect sizes are described as mean 
difference [95% confidence intervals (CI)], and Cohen’s d values. Statistical analyses were two-tailed, 























The study cohort was demographically representative of a typical post-operative Western esophageal 
cancer population, with a mean age of 63 years, 7 (87.5%) males, and 6 with adenocarcinoma (75%) 
(Table 1). While pre-operatively participants tended to be overweight with a mean BMI of 27.2 
kg/m
2
, this fell to 22.4 kg/m
2
 by the first study visit. At a median of 23.6 months post-operatively, the 
average weight loss from pre-operative weight was 15.5%. Pathological and treatment characteristics 
are outlined in Table 1. 
 
Plasma glucagon-like peptide-1 
Although the shape of the post-prandial GLP-1 response curve was altered at the week 4 timepoint 
(P=0.01), overall suppression with treatment as determined by the area under the curve was not 
significant (P=0.08) (Figure 2). On post-hoc analysis, GLP-1 response at 30 minutes was lower after 
treatment (P<0.001). This is corroborated by a trend towards the suppression of early AUC (up to 60 
minutes post meal ingestion, P=0.053), but no evidence of a significant difference in overall AUC 
(P=0.30). There was also a trend towards a reduction in peak post-prandial GLP-1 (median [IQR] – 
week 0: 145 [93 – 192] pM vs. week 4: 135 [72 - 152] pM, P=0.055). Post-mixed meal appetite and 
nausea VAS scores did not differ between visits (Supplementary Figure S4 (39)). 
 
Plasma glucose and insulin  
Post-prandial plasma glucose concentration curves were different at week 4, relative to pre-treatment 
(P=0.046), with a more sustained post-prandial glycemic response to 60 minutes post-prandially 
(week 0: 5.6 (1.4) mmol/L vs. week 4: 7.5 (2.1) mmol/L, P <0.001) (Figure 3A). Treatment was not 
associated with a reduction in fasting or peak post-prandial glucose concentrations (both P >0.99). 
There were no cases of biochemical reactive hypoglycemia before or after treatment, defined as a 






















Post-prandial plasma insulin concentrations were not significantly different at week 4, compared with 
week 0 (P=0.69) (Figure 3B). However, there was a significant treatment x time effect, with a 
delayed peak insulin at week 4 (P <0.001), with the concentration at 30 minutes, on post-hoc analysis, 
approximately two-fold higher pre-treatment (mean (SD), week 0: 97.2 (51.8) vs. week 4: 44.0 (33.7) 
mU/L, P <0.001), and the concentration at 60 minutes almost four-fold higher post-treatment (week 0: 
21.6 (11.2) vs. week 4: 79.5 (38.3) mU/L, P <0.001). 
 
Body anthropometry and composition 
There were no significant changes in body weight after four weeks of treatment with Octreotide LAR 
(Table 2). There was an increase in waist-hip ratio (WHR) after four weeks of treatment (mean (SD), 
week 0: 0.88 (0.1) vs. week 4: 0.90 (0.1), P=0.02), although no change in absolute or relative body fat 
mass, or in skeletal muscle mass was observed. 
 
Eating behavior 
Motivation to eat 
No difference was observed in appetitive behavior, as measured by PRT breakpoint (the last 
completed ratio), after four weeks of clinical treatment (median [IQR], week 0: 960 [400 – 1280] vs. 
week 4: 640 [320 – 1120], P=0.41) (Figure 4). Absolute number of clicks did not differ before and 
after treatment (mean (SD), week 0: 1479 (707) vs. week 4: 1251 (716) clicks, P=0.52) (Figure 4). 
These results occurred in the context of analogous pre-PRT plasma GLP-1 concentrations (P=0.25) 
and VAS appetite ratings, the latter of which suggests no change in ‘pleasure’ to receive food 
associated with treatment (P=0.46). More significant plasma GLP-1 suppression with Octreotide LAR 
correlated significantly with an increase in eating motivation as measured by total clicks during the 
PRT (P=0.026, R
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Ad libitum food intake and macronutrient preference 
There was no difference in total energy intake during the ad libitum buffet meal before and after 
treatment (mean (SD), week 0: 796 (280) kcal vs. week 4: 847 (229) kcal, P=0.46) (Figure 5A), nor 
any change in macronutrient selection (P=0.26) (Figure 5B).  
 
Importantly, % fat intake was not related to relevant symptoms, such as diarrhea (P=0.70), loss of 
appetite (P=0.58), and Sigstad score (P=0.18), but was significantly associated with increased reflux-




Functional MRI tasks 
In the food picture evaluation fMRI task, functional region of interest (fROI) analysis using 2-factor 
repeated-measures ANOVA, including ROI and treatment visit as within subject factors, there were 
no significant ROI x visit interactions for the BOLD signal for any of the following contrasts: high-
energy food vs. low-energy food [F(2.4, 16.4) = 0.713, P=0.525], high- or low-energy food vs. object 
[F(2.8, 19.3) = 1.62, P=0.314], high-energy food vs. object [F(2.8, 19.5) = 2.07, P=0.14], and low-
energy food vs. object [F(2.8, 19.6) = 0.411, P=0.73] (Figure 6A-D). There were also no significant 
main effects of visit for any of these picture contrasts, independent of ROI (see Figure 6 legend for 
statistics). Thus, treatment with Octreotide LAR had no significant effect of high-energy or low-
energy food cue reactivity. 
 
For food picture appeal rating (relative to objects), there was also no significant energy density x visit 
interaction [F(1,7) = 2.396, P=0.166] nor main effect of visit (independent of energy density) [effect 





















Thus, treatment with Octreotide LAR had no effect on food appeal independent or dependent on 
energy density. 
 
In whole-brain analysis for the food picture evaluation fMRI task, there were no clusters displaying 
significant differences in BOLD signal (voxel-wise false discovery rate (FDR) P<0.05; nor cluster-
wise family wise error (FWE) Z>2.1, P<0.05) between visits for the high-energy > low-energy food, 
high-energy food > object, low-energy food > object, nor any food (high-energy or low-energy food) 
> object picture contrasts. 
 
The control auditory-motor-visual (AMV) fMRI task was designed to account for non-specific BOLD 
signal changes between visits.(38) In fROI analysis, no significant differences in BOLD signal within 
any fROI was found comparing before and after treatment (ROI x visit interaction: P=0.44, main 
effect of visit: P=0.46, Figure 6E). 
 
Potential confounding variables 
There were no significant differences between visits in variables that could have confounded BOLD 
signal responses: pre-fMRI composite appetite VAS ratings (median (range), week 0: 6.6 (2.4 – 7.7) 
vs. week 4: 5.4 (2.7 – 7.9), P=0.64), pre-fMRI nausea and sleep VAS ratings (Supplementary Figure 
S4 (39)), BMI (P=0.21), % body fat mass (P=0.58), pre-scan energy intake (400 kcal at mixed meal 
given to all participants), head motion during food picture evaluation fMRI task [average relative 
motion (mm per volume), median (IQR) week 0: 0.09 (0.08, 0.15), week 4: 0.14 (0.08, 0.16), 























Post-prandial symptoms and health-related quality of life 
There were no significant differences in reported HRQL outcomes before vs. after treatment with 
Octreotide LAR, with global HRQL remaining stable (P=0.94) (Table 3).  
 
When comparing key appetite and nutrition-related patient-reported outcomes, Sigstad score was 
lower after treatment (median (range), week 0: 12 (2-28) vs. week 4: 8 (3-18), P=0.039) (Figure 7, 
Table 3). The degree of plasma GLP-1 suppression (delta AUC 0-150 mins) did not correlate with 
improvement in Sigstad score (P=0.58, R
2
=0.05). However, EORTC symptom appetite loss severity 
scores did not change significantly with Octreotide LAR treatment: median (range) week 0: 66.7 (0 – 























This pilot study shows that it is feasible to characterize the gut-brain axis and its relation to food 
reward and eating behavior in a cohort post esophagectomy. Notwithstanding, 10mg Octreotide LAR 
was not sufficient to change gut hormone response, body weight, appetitive behavior or ad libitum 
food intake. 
 
Somatostatin analogues have been used in surgical contexts to reduce post-prandial symptoms and can 
have beneficial nutritional effects, including the restoration of post-operative weight loss (30, 42). 
There has, however, historically been no method to systematically analyze the factors underlying their 
potential beneficial effects in the context of major upper gastrointestinal resection. This limits the 
ability to appropriately target treatment to patients who are most likely to derive benefit. Recent 
developments in our understanding of how alterations in gut-brain axis signaling may be implicated in 
the pathophysiology of post-esophagectomy symptomatology and malnutrition (11), should enable a 
more systematic approach to therapeutic interventions.  Moreover, while studies at least suggest a 
compelling rationale for long-term nutritional benefit with the use of Octreotide LAR, through 
mitigation of the exaggerated post-operative gut hormone response, this remains to be proven.   
 
In this study, the first to assess Octreotide LAR in this context, the scientific thesis was that 
Octreotide administration, shown previously to acutely inhibit GLP-1 secretion and increase ad 
libitum food intake among patients post esophagectomy, would suppress gut hormones and potentially 
facilitate weight regain. In this model, GLP-1 was the preferred marker to represent general post-
prandial gut hormone secretion. We anticipated that significant plasma GLP-1 suppression at the 
mixed meal challenge would also be associated with increased brain reward system food cue 
reactivity and eating behavioral changes. However, four weeks after a treatment dose of long-acting 
Octreotide, GLP-1 secretion, though blunted in the early post-prandial phase, was not sufficiently 





















system food cue reactivity and eating behavior, there were no significant changes in body weight or 
muscle mass. Given the suboptimal plasma GLP-1 suppression, the observations described herein 
cannot be asserted to reflect observations occurring despite gut hormone suppression. This is 
important to bear in mind when interpreting these findings and could feasibly underlie the lack of a 
positive effect with regards to body weight and composition with treatment. This is particularly 
pertinent as the studies describing an impact of short-acting Octreotide did demonstrate significant 
GLP-1 attenuation (27, 28). There was no clear precedent on which to base the dosing in this clinical 
context. The 10mg dose was selected based on weighing the risks and potential benefits of treatment. 
In an already nutritionally vulnerable cohort, the ethical principle of non-maleficence guided us in 
choosing a dose less likely to elicit adverse effects. In a study of patients post gastrectomy, 10mg of 
Octreotide was sufficient to improve quality of life within four weeks and those requiring up-titration 
to 20mg were less likely to derive benefit overall (30). As such, in the clinical context, patients were 
commenced on a 10mg dose, and this trial of therapy continued for one month at which point a shared 
decision was made with the patient based on subjective and objective treatment benefit. Future longer-
term studies, allowing dose titration to avoid side effects, will be required to determine whether a 
prolonged duration of treatment and/or higher doses of Octreotide may induce observable changes in 
eating behaviour and body composition. 
 
Post-prandial hypoglycemia is a phenomenon that occurs after foregut surgery and may be related to 
exaggerated post-prandial gut hormone release (43, 44). In the current study, however, there were no 
cases of biochemical or symptomatic hypoglycemia post-prandially. Nonetheless, a minimally potent 
dose of a long-acting somatostatin analogue was associated with an increase in post-prandial plasma 
glucose concentrations and a corresponding alteration of the pattern of post-prandial plasma insulin 
dynamics, delaying its peak.  
 





















hedonic signaling pathways of food reward (12, 13, 17, 45). Indeed, in related surgeries, such as 
Roux-en-Y gastric bypass (RYGB) surgery, attenuation of the exaggerated post-prandial GLP-1 (and 
PYY) gut hormone secretion is associated with increased brain reward system food cue reactivity and 
food appeal (12). This study used an established fMRI paradigm to assess food cue reactivity (12, 36-
38), assessing BOLD signal in a priori regions of interest within the brain reward system, to explore 
the relationship of medium-term Octreotide LAR therapy with anticipatory food reward, but did not 
find a significant increase, or even a trend for an increase, in BOLD signal to high-energy or low-
energy foods to corroborate previous findings. However, the degree of plasma gut hormone 
suppression achieved was notably less, and as such these findings are not presented as an attempt to 
rebut previous work on this question. Future studies will need to explore the use of higher doses to 
ascertain the potential role for long-acting Octreotide in improving outcomes by influencing food 
reward signaling, as well as increasing the number of participants. 
 
Eating behavior is the final step along the pathway assessed in this study. This comprised the PRT, 
exploring appetitive behavior, and an ad libitum buffet meal, to directly measure food intake and food 
selection. The latter is subject to external conditioned and/or unconditioned influences, such as post-
prandial symptoms creating food avoidance, or social cues or contexts, respectively (21, 46). As 
noted, previous work in patients after esophagectomy reported a 1.5-fold increase in ad libitum energy 
intake and increased motivation to receive a sweet-fat stimulus in the fed state with acute Octreotide 
administration (27, 28), mirroring similar observations in RYGB cohorts (12). The findings outlined 
in this paper suggest there is an association between the degree of gut hormone suppression obtained 
and alterations in eating behavior, as those with greater plasma GLP-1 suppression were more likely 
to increase their motivation to receive a food reward. However, this finding did not translate into a 
subsequent increase in energy intake in these participants during the buffet meal. 
 





















plasma GLP-1 suppression, the methodology previously utilized differed. This study utilized a real-
world buffet style meal based on patient preferences, while previous work has used a method 
involving investigator-controlled and timed provision of a single food item until satiation was reached 
by the participant. This distinction introduces variables such as conditioned food avoidance, a 
phenomenon whereby learned behavior over time in an attempt to mitigate against post-ingestive 
symptoms can lead to active avoidance of certain foods or food quantities (46). Interestingly, and 
relevant to the complexity and myriad factors involved in eating behavior, at the baseline visit, energy 
intake was not significantly associated with the relative or absolute increase in plasma GLP-1 at the 
meal suggesting that participant’s food ingestion was more strongly influenced by other factors 
besides satiety signaling. 
 
Prior longitudinal work in an esophagectomy cohort has shown that the exaggerated enteroendocrine 
response corresponds with important appetitive symptoms, such as early satiety, and correlates with 
Sigstad score (11). In this study, treatment with Octreotide LAR was associated with a 30% relative 
reduction in Sigstad score, reflective of acute post-prandial symptom burden. Although limited by the 
subjective nature of questionnaire data, if this potential finding is validated in larger studies, this 
represents a promising option for the management of postprandial symptoms. Indeed, prolonged 
exposure to a reduced symptom profile may manifest in more profound positive changes in eating 
behavior and body weight over time. 
 
Several limitations must be acknowledged, which should be viewed in the context of this as a pilot 
study. This was not a randomized or controlled study, thus findings – positive and negative – must be 
interpreted with caution, recognizing its inability to infer causality. Given the relatively small sample 
size, negative results must be interpreted with caution as a Type II error cannot be excluded. The 
unblinded uncontrolled design exposes these findings to the order effect, whereby participants may 





















absence of differences in VAS scores between visits does indicate that the potential of bias at the 
buffet meal may be less likely. As noted, the degree of gut hormone suppression achieved with 
clinical treatment was less than expected, which also limits the interpretation of these findings. This 
factor precludes the representation of any observations herein as associated with significant 
attenuation of the post-prandial gut hormone response. We have discussed them instead in the context 
of Octreotide LAR therapy. However, this absence of evidence of suppression at the four-week 
timepoint does not serve as evidence of absence of suppression at some point earlier in the treatment 
period. 
 
In conclusion, this pilot study outlines, in a post-esophagectomy cohort with significant weight loss, 
the parallel characterization of multiple levels of the gut-brain axis and eating behavior, which will 
benefit future work aiming to better elucidate the role of these processes in the etiology of post-
operative malnutrition. Moreover, it provided insight into the impact of a 4 week 10mg Octreotide 
LAR treatment course on the postprandial gut hormone response, food reward, and eating behavior. 
Though gut hormone suppression was suboptimal, patients did not exhibit altered body weight or 
appetitive behavior. These findings may be used to inform the design of future studies investigating 
the value of gut hormone attenuation as a therapy for malnutrition and weight loss, while also 
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Figure 1. Study protocol flowchart for ‘REWARD’ study.  
fMRI, functional magnetic resonance imaging; HR-QL, health-related quality of life; mGSRS, 
modified gastrointestinal rating scale; LAR, long-acting release. PRT, progressive ratio task. 
 
Figure 2. Post-prandial plasma GLP-1 before and after treatment with octreotide LAR. 
(A) Post-prandial plasma total GLP-1 secretion, (B) peak postprandial GLP-1, and (C) total post-
prandial area under curve (AUC) from before to 150 minutes, and (D) early AUC of post-prandial 
GLP-1 secretion before and after treatment with Octreotide LAR (n=8). Panel A: The grey dotted line 
represents consumption of the standardized 400 kcal mixed meal. Repeated measures two-way 
ANOVA with post-hoc Bonferroni’s multiple comparisons test: mean difference [95% confidence 
interval] 8.47 [-0.91, 17.85], F[1, 42] = 3.32, P=0.076, Cohen’s d = -0.23. T=30, mean difference 
[95% CI] 53.37 [21.85, 84.89, P<0.001]. Panel B: Mean ± SEM, paired t test: mean difference [95% 
CI] -21.81 [-45.33, 1.70], t = 2.19, df = 7, P=0.064, Cohen’s d = -0.44. Panel C: Mean ± SEM, paired 
t test: mean difference [95% CI] -44.61 [-90.09, 0.87], t = 2.32, df = 7, P=0.053, Cohen’s d = -0.75. 
Panel D: Mean ± SEM, paired t test: mean difference [95% CI] -43.93 [-137.3, 49.4], t = 1.11, df = 7, 
P=0.30, Cohen’s d = -0.42.  Abbreviations: GLP-1, glucagon-like peptide-1. 
 
Figure 3. Post-prandial plasma glucose and insulin before and after treatment with octreotide 
LAR.  
Time course of plasma (A) glucose and (B) insulin before and after standardized 400 kcal mixed meal 
with grey dotted line representing time of meal consumption (n=8). (A) Post-prandial plasma glucose 
concentrations were higher after treatment with octreotide LAR. 2-way repeated measures ANOVA 





















0.763, -0.007], F[1, 42] = 4.23, P=0.046, Cohen’s d = 0.26. (B) There was a treatment x time effect 
on post-prandial plasma insulin after treatment with a delayed peak, but no overall difference in post-
prandial concentrations after treatment: mean difference [95% CI] -1.454 [-8.791, 5.883], F[1, 42] = 
0.16, P=0.69, Cohen’s d = 0.04. At T=30, post-treatment insulin concentration was significantly 
lower (mean difference [95% CI]: 53.29 [28.63, 77.95], P <0.001), while at T=60 insulin was 
significantly higher after treatment (mean difference [95% CI]: -57.89 [-82.55 to -33.23], P <0.001). 
 
Figure 4. Progressive ratio task before and after treatment with octreotide LAR.  
 (A) Breakpoint and (B) total clicks in progressive ratio task (PRT) before and after treatment with 
octreotide LAR. Data given as median ± IQR (interquartile range), n=8. (A) Wilcoxon matched pairs 
signed rank test: P=0.41, Cohen’s d = -0.47, (B) mean ± SEM, paired t test: mean difference [95% 
CI] -228 [-1030, 575.2], t = 0.67, df = 7, P=0.52, Cohen’s d = -0.32. 
 
Figure 5. Ad libitum buffet meal before and after treatment with octreotide LAR. 
Octreotide LAR treatment was not associated with (A) a change in total energy intake at ad libitum 
buffet meal (mean ± SEM, paired t test: mean difference [95% CI] 50.65 [-101.0, 202.3], t = 0.79, df 
= 7, P=0.46), nor (B) macronutrient selection at ad libitum buffet meal  2-way (repeated measures 
ANOVA with post-hoc Bonferroni’s multiple comparisons test: mean difference [95% confidence 
interval] -0.095 [-1.604, 1.414], F[1, 28] = 0.02, P=0.89, Cohen’s d < 0.01); n=8. Abbreviations: 
CHO, complex carbohydrates. 
 
Figure 6. Food picture evaluation and auditory-motor-visual fMRI tasks before and after 





















There were no significant differences in the magnitude of BOLD signal (%) in a priori regions of 
interest ROI) in the (A-D) food picture evaluation functional MRI task (amygdala, anterior insula, 
orbitofrontal cortex (OFC), putamen, nucleus accumbens, and caudate) before vs. after treatment for 
contrasts: (A) high-energy vs. low-energy food, mean difference [95% confidence interval] 0.038 [-
0.096 – 0.173], F[1, 7] = 0.46, P=0.52, Cohen’s d = -0.55, (B) high-energy or low-energy foods (vs. 
objects), mean difference [95% CI] 0.079 [-0.032, 0.191], F[1, 7] = 2.82, P=0.14, Cohen’s d = -1.65, 
(C) high-energy foods (vs. objects), mean difference [95% CI] 0.097 [-0.007, 0.200], F[1, 7] = 4.88, 
P=0.06, Cohen’s d = -1.54, and (D) low-energy foods (vs. objects), mean difference [95% CI] 0.062 
[-0.094, 0.218], F[1, 7] = 0.89, P=0.38, Cohen’s d = -1.14, nor (E) auditory-motor-visual control 
functional MRI task  (bilateral superior temporal gyrus in auditory task, left precentral gyrus in motor 
task, and bilateral lingual gyrus in visual task), nor (F) appeal rating of low-energy or high-energy 
foods (vs. objects) in food picture evaluation functional MRI task. Analyses used 2-way repeated 
measures ANOVA including (A-E) visit and ROI, or (F) visit and energy density, as within subject 
factors with post-hoc Fisher least-significant difference test (n=8). Abbreviations: Amy, amygdala; 
AMV, auditory-motor-visual; BOLD, blood oxygen level-dependent; Caud, caudate; ED, energy 
density; HE, high-energy; Ins, anterior insula; LE, low-energy; Lingual, lingual gyrus; LpreCG, left 
precentral gyrus; NAcc, nucleus accumbens; OFC, anterior orbitofrontal cortex; Put, putamen; STG, 
superior temporal gyrus posterior division. 
 
Figure 7. Sigstad dumping syndrome score before and after treatment with octreotide LAR.  
Sigstad score was significantly lower after 4 weeks of treatment. Median ± interquartile range, 






















Table 1: Clinicopathological characteristics of the study cohort 
 Cohort 
 N = 8 
Clinical Characteristics  
Age, mean (SD) 62.8 (9.4) 
Sex, n (%)  
     Female 1 (12.5) 
     Male 7 (87.5) 
Body weight at 1
st
 study visit, kg, mean (SD) 68.6 (12.8) 
BMI at 1
st
 study visit, kg/m
2
, mean (SD) 22.4 (2.8) 
Pre-illness BMI, kg/m
2
, mean (SD) 27.2 (3.6) 
Preoperative BMI, kg/m
2
, mean (SD) 26.5 (3.0) 
Post-diagnosis body weight loss (%), mean (SD) 17.5 (6.1) 
Post-operative body weight loss (%), mean (SD) 15.5 (5.8) 
Time since operation, months, median (range) 23.6 (7.3) 
Pathology  
Adenocarcinoma, n (%) 6 (75.0) 
SCC, n (%) 2 (25.0) 
  
Operation, n (%)  
    2-stage oesophagectomy 3 (37.5) 
    Transhiatal oesophagectomy 4 (50.0) 
    3-stage oesophagectomy 1 (12.5) 
Neoadjuvant therapy, n (%) 2 (25.0) 
   Chemoradiotherapy 1 (50.0) 
   Chemotherapy 1 (50.0) 






















Table 2. Body weight, composition, and anthropometry in patients before and after 
treatment with long-acting Octreotide. 
 Week 0 Week 4  
 N = 8 N = 8 P-value 
Anthropometry    
Body weight, kg, mean (SD) 68.6 (12.8) 69.2 (13.4) 0.129 
BMI, kg/m
2
, mean (SD) 22.4 (2.6) 22.7 (3.0) 0.207 
% Body weight change, mean (SD) - 0.68 (1.3) 0.185* 
Mid-upper arm circumference, cm, mean (SD) 25.6 (1.4) 25.8 (2.4) 0.785 
Waist:Hip Ratio, mean (SD) 0.88 (0.1) 0.90 (0.1) 0.024 
    
Body Composition    
Skeletal muscle mass, kg, mean (SD) 25.4 (5.8) 25.5 (6.1) 0.914 
Fat-free mass, kg, mean (SD) 52.7 (9.8) 52.6 (10.2) 0.965 
Fat mass, kg, mean (SD) 16.0 (4.9) 16.6 (5.0) 0.406 
Fat mass, %, mean (SD) 23.3 (5.2) 23.8 (5.3) 0.582 



























Table 3. Selected health-related quality of life and nutrition-specific symptoms before 
and after treatment with Octreotide LAR 
 
Week 0  
N = 8 
Week 4 






Quality of life outcomes, 




Health-related quality of life 62.5 (50.0 – 91.7) 66.7 (41.7 – 83.3) 1.0 (10.4) 0.938 
Role function 91.7 (33.3 – 
100.0) 
100.0 (33.3 – 
100.0) 
6.3 (25.1) 0.625 
Physical function 90.0 (66.7 – 
100.0) 
86.7 (46.7 – 100.0) -3.3 (8.7) 0.719 
Social function 66.7 (16.7 – 
100.0) 
66.7 (33.3 – 100.0) -1.0 (11.3) 0.750 
Cognitive Function 83.3 (50.0 – 
100.0) 
66.7 (50.0 – 100.0) -4.2 (11.8) 0.500 
Dumping syndrome     
Sigstad Score, median (range) 12 (2 – 28) 8 (3 – 18) -3.9 (3.7) 0.039 
Clinically significant Sigstad 
score >7, n (%) 
7 (87.5) 4 (50.0) - 0.282
#
 
Select EORTC symptoms,  
median (range) 
    
Appetite loss 66.7 (0.0 – 66.7) 0.0 (0.0 – 66.7) -33.3 (30.9) 0.063 
Early satiety 66.7 (0.0 – 66.7) 33.3 (0.0 – 100.0) -8.3 (38.8) 0.359 
Eating difficulties 29.2 (8.3 – 41.7) 33.3 (8.3 – 50.0) 3.1 (13.3) 0.813 
Nausea 16.7 (0.0 – 33.3) 16.7 (0.0 – 33.3) <0.1 (8.9) 0.563 
Diarrhea 0.0 (0.0 – 33.3) 33.3 (0.0 – 66.7) 14.3 (17.8) 0.250 
Reflux (acid / bile) 33.3 (0.0 – 50.0) 16.7 (0.0 – 83.3) <0.1 (17.8) 0.938 
Dysphagia 0.0 (0.0 – 11.1) 0.0 (0.0 – 11.1) <0.1 (4.7) 0.500 























exact test. For quality of life outcomes, possible scores range from 0 – 100, with 100 representing an 
optimal score. Abbreviations: EORTC, European Organization for Research and Treatment of 
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High vs. low-energy food
Week 0
Week 4
Visit: P = 0.519
ROI*Visit: P = 0.525
















High-energy food vs. Object
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Visit: P = 0.063


















Auditory Motor         Visual
Visit: P = 0.457
ROI*Visit: P = 0.436
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Low-energy food vs. Object
Week 0
Week 4
Visit: P = 0.376






























Visit: P = 0.496



































/dgaa697/5916397 by guest on 02 O
ctober 2020
